Media Relations News Releases Year: - Any -202120202019201820172016 Items per page 102550 Sep 19, 2021 Summary ToggleNovartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer Jun 2, 2021 Summary ToggleNovartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients May 18, 2021 Summary ToggleNovartis reaches milestone delivery of 1 billion courses of antimalarial treatment Jan 29, 2021 Summary ToggleNovartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis Dec 9, 2020 Summary ToggleNovartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer Nov 19, 2020 Summary ToggleNew data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases Nov 13, 2020 Summary ToggleNew Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender Nov 2, 2020 Summary ToggleNovartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention Sep 11, 2020 Summary ToggleNovartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS) Sep 11, 2020 Summary ToggleNovartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
